Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
2003 1
2004 1
2005 3
2006 4
2007 4
2008 3
2009 3
2010 3
2011 3
2012 2
2013 2
2014 2
2015 6
2016 5
2017 4
2018 3
2019 10
2020 9
2021 18
2022 18
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Results by year

Filters applied: . Clear all
Page 1
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Sims JR, et al. JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239. JAMA. 2023. PMID: 37459141 Free PMC article.
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. N Engl J Med. 2022. PMID: 35921451 Clinical Trial.
Psychogenic movement disorders.
Peckham EL, Hallett M. Peckham EL, et al. Neurol Clin. 2009 Aug;27(3):801-19, vii. doi: 10.1016/j.ncl.2009.04.008. Neurol Clin. 2009. PMID: 19555832 Free PMC article.
Essential tremor, deceptively simple...
Nahab FB, Peckham E, Hallett M. Nahab FB, et al. Among authors: peckham e. Pract Neurol. 2007 Aug;7(4):222-33. doi: 10.1136/jnnp.2007.124693. Pract Neurol. 2007. PMID: 17636137 Review.
Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies.
Rascol O, Tönges L, deVries T, Jaros M, Quartel A, Jacobs D; ALLAY-LID I and ALLAY-LID II study groups. Rascol O, et al. Parkinsonism Relat Disord. 2022 Mar;96:65-73. doi: 10.1016/j.parkreldis.2022.01.022. Epub 2022 Feb 8. Parkinsonism Relat Disord. 2022. PMID: 35227940 Free article. Clinical Trial.
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. Front Neurol. 2021. PMID: 34659081 Free PMC article.
The use of unequal randomisation in clinical trials--An update.
Peckham E, Brabyn S, Cook L, Devlin T, Dumville J, Torgerson DJ. Peckham E, et al. Contemp Clin Trials. 2015 Nov;45(Pt A):113-22. doi: 10.1016/j.cct.2015.05.017. Epub 2015 May 28. Contemp Clin Trials. 2015. PMID: 26027788 Review.
Out of pocket expenses in obsessive compulsive disorder.
Heslin M, Gellatly J, Pedley R, Knopp-Hoffer J, Hardy G, Arundel C, Bee P, McMillan D, Peckham E, Gega L, Barkham M, Bower P, Gilbody S, Lovell K, Byford S. Heslin M, et al. Among authors: peckham e. J Ment Health. 2022 Oct;31(5):607-612. doi: 10.1080/09638237.2020.1755028. Epub 2020 May 1. J Ment Health. 2022. PMID: 32357807 Free article.
108 results